Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P37268

UPID:
FDFT_HUMAN

ALTERNATIVE NAMES:
FPP:FPP farnesyltransferase; Farnesyl-diphosphate farnesyltransferase; Farnesyl-diphosphate farnesyltransferase 1

ALTERNATIVE UPACC:
P37268; B3KQ95; B4DJE5; B4DT56; B7Z1J3; Q96GT0

BACKGROUND:
The enzyme squalene synthase, with alternative names such as FPP:FPP farnesyltransferase, plays a crucial role in the synthesis of sterols by catalyzing the condensation of two farnesyl pyrophosphate molecules to form squalene. This reaction marks the divergence point from primary to secondary metabolism in the sterol biosynthesis pathway.

THERAPEUTIC SIGNIFICANCE:
Linked to squalene synthase deficiency, a rare autosomal recessive disorder characterized by significant developmental and metabolic anomalies, the study of squalene synthase offers a promising avenue for the development of novel therapeutic interventions aimed at correcting the underlying metabolic disturbances.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.